TiumBio Completes Dosing in Hemophilia New Drug Phase 1a Clinical Trial

TIUM Bio announced on the 25th that it has completed the last patient dosing in the Phase 1a clinical trial of TU7710, a hemophilia treatment candidate.

TiUM Bio logo [Photo by TiUM Bio]

This clinical trial was conducted on 40 healthy adult males. The purpose was to evaluate the safety, pharmacokinetics, and pharmacodynamic characteristics of the drug by increasing the administered dose from 100 μg/kg (Cohort 1) to 1600 μg/kg (Cohort 5) of TU7710.

TU7710 is a coagulation factor VII treatment. It was developed to treat patients who are ineffective to existing treatments due to neutralizing antibodies occurring in 30% of hemophilia patients who congenitally lack coagulation factors and cannot stop bleeding. In particular, existing treatments have the disadvantage of requiring frequent dosing because the drug's half-life in the blood is only about 2.3 hours on average, but TU7710 has been developed as a long-acting treatment that extends the half-life by approximately 6 to 7 times, thus securing market competitiveness.

Kim Hoon-taek, CEO of TIUM Bio, said, “We secured safety data as expected in the Phase 1 trial of TU7710 and confirmed the longer half-life compared to existing treatments. We will accelerate the development of innovative hemophilia drugs and quickly generate not only commercial value but also business development achievements.”

This content was produced with the assistance of AI translation services.